PMID: 7540295Jan 1, 1995Paper

Adrenal medulla is involved in the aldosterone secretagogue effect of substance P

Peptides
G MazzocchiG G Nussdorfer

Abstract

Substance P (SP) increased aldosterone secretion of rat adrenal slices, but not of isolated zona glomerulosa cells, and this effect was annulled by two specific antagonist of SP (SP-A). Both tissue preparations displayed an aldosterone secretory response to isoprenaline (IP) that was blocked by l-alprenolol (AL). AL reversed the aldosterone response of adrenal slices to IP, SP, or IP plus SP, whereas SP-A only suppressed that to SP. Quarters of adrenocortical autotransplants, which are completely deprived of chromaffin cells, showed an aldosterone response to IP, but not to SP. These findings suggest that the mechanism underlying the aldosterone secretagogue action of SP probably involves the stimulation of catecholamine release by adrenal medulla chromaffin cells.

References

Mar 1, 1992·The Journal of Endocrinology·D S JessopS L Lightman
May 4, 1990·Neuroscience Letters·D P GeraghtyE Burcher
Jul 15, 1991·Biochemical and Biophysical Research Communications·R HåkansonK Folkers
Jan 1, 1990·The Journal of Endocrinology·J P Hinson
Sep 1, 1988·Peptides·G G NussdorferP Rebuffat
Jan 1, 1988·Annual Review of Neuroscience·J E Maggio
Jun 1, 1987·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·N Gallo-PayetH Isler
Jan 22, 1982·European Journal of Pharmacology·S CaranikasD Regoli

❮ Previous
Next ❯

Citations

Mar 1, 1996·The Journal of Steroid Biochemistry and Molecular Biology·M K KodjoH Vaudry
Jul 15, 1998·Peptides·G G Nussdorfer, L K Malendowicz
May 28, 2003·Microscopy Research and Technique·G P Vinson
Dec 1, 1995·Neuropeptides·L K MalendowiczW Butowska
May 7, 1998·Endocrine Reviews·M Ehrhart-BornsteinG P Vinson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.